Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia

INTRODUCTION: Solanezumab treatment was previously shown to significantly increase total (bound + unbound) cerebrospinal fluid (CSF) levels of amyloid β (Aβ)(1–40) and Aβ(1–42) in patients with mild to moderate Alzheimer's disease dementia yet did not produce meaningful cognitive effects. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Willis, Brian A., Sundell, Karen, Lachno, D. Richard, Ferguson-Sells, Lisa R., Case, Michael G., Holdridge, Karen, DeMattos, Ronald B., Raskin, Joel, Siemers, Eric R., Dean, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Featured Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258891/
https://www.ncbi.nlm.nih.gov/pubmed/30511011
http://dx.doi.org/10.1016/j.trci.2018.10.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258891/
https://www.ncbi.nlm.nih.gov/pubmed/30511011
http://dx.doi.org/10.1016/j.trci.2018.10.001

Ejemplares similares